All In Biotech

Drug Trial Radar · NCT07722728

A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia

An Open-label, Randomized, Single-dose (Long-acting Injectable) or Multiple-dose (Oral) Clinical Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

Aug 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Bostal Drug Delivery Co., LtdIndustry
Sponsor type
Industry
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is to evaluate the pharmacokinetic profile of B2227 Extended-Release Injectable Suspension against Vraylar® Cariprazine capsules of AbbVie Inc. in participants with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • 30 mg B2227Drug

    Single-dose; Subcutaneous

  • 70 mg B2227Drug

    Single-dose; Subcutaneous

  • 150 mg B2227Drug

    Single-dose; Subcutaneous

  • Vraylar® 1.5 mgDrug

    Multiple-dose, Oral

  • Vraylar® 3.0 mgDrug

    Multiple-dose, Oral

  • Vraylar® 4.5 mgDrug

    Multiple-dose, Oral

  • Vraylar® 6.0 mgDrug

    Multiple-dose, Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: Pre-dose to 190 days post-dose
  2. TmaxTime frame: Pre-dose to 190 days post-dose
  3. AUC0-lastTime frame: Pre-dose to 190 days post-dose
  4. AUC0-infinityTime frame: Pre-dose to 190 days post-dose
  5. T1/2Time frame: Pre-dose to 190 days post-dose
  6. KelTime frame: Pre-dose to 190 days post-dose
  7. Vd/FTime frame: Pre-dose to 190 days post-dose
  8. MRTTime frame: Pre-dose to 190 days post-dose
  9. AUC_%Extrap_obsTime frame: Pre-dose to 190 days post-dose
  10. Cmax,ssTime frame: Pre-dose to 57 days post-dose
  11. Cmin,ssTime frame: Pre-dose to 57 days post-dose
  12. Cavg,ssTime frame: Pre-dose to 57 days post-dose
  13. AUC24hTime frame: Pre-dose to 57 days post-dose
  14. FluctuationTime frame: Pre-dose to 57 days post-dose
  15. SwingTime frame: Pre-dose to 57 days post-dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.